Please login to the form below

Not currently logged in

gene sequencing

This page shows the latest gene sequencing news and features for those working in and with pharma, biotech and healthcare.

UK ‘unicorn’ Oxford Nanopore bags $65m backing from Amgen

UK ‘unicorn’ Oxford Nanopore bags $65m backing from Amgen

Big biopharma investment good news for gene sequencing company. Amgen has taken a £50m ($66m) minority stake in Oxford Nanopore Technologies (ONT), a UK company making waves in the genetic sequencing ... Illumina and smaller players like Pacific

Latest news

More from news
Approximately 7 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Under pressure Under pressure

    It is based on technologies, such as bioinformatics, gene sequencing, biomarkers and synthetic biology that make systems biology and systems medicine possible.

  • Harnessing complexity Harnessing complexity

    DNA changes can only be detected with sophisticated machinery that relies on advanced techniques such as real time polymerase chain reactions (PCR) and, increasingly, full gene sequencing. ... Next Generation Sequencing has been gradually increasing in

  • Pharma deals during February 2014 Pharma deals during February 2014

    In the meantime, Roche's pRED group will make use of Discuva's development technology, which uses gene sequencing and bioinformatics to identify targets for multi-drug resistant Gram-negative bacteria,

  • Pharma deals during September 2013 Pharma deals during September 2013

    Strengthening another of its business units, Roche's diagnostic arm announced a licensing deal with Pacific Bioscience for human in vitro diagnostic (IVD) gene sequencing technology, paying $35m upfront and additional ... Antisense technology is

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...